Monographs & Whitepapers
Navigating the Global Threat of Typhoid Fever
This Special Report reviews the medical and public health aspects of typhoid and paratyphoid fever, focusing on means of prevention to control the spread of infection.
JULY 28, 2025
The Critical Role of HIV Testing And Reporting in Clinical Practice: Insights From Virology Laboratories
This Special Report discusses the role of viral load testing, the challenges in interpreting results, and best practices for HIV test result reporting to optimize patient care and advance HIV eradication.
JUNE 27, 2025
Optimizing Management of Invasive Candidiasis With Rezafungin for Injection
This monograph discusses the treatment landscape for candidemia and invasive candidiasis and highlights clinical data on the efficacy and safety of using rezafungin for injection for affected patients who have limited or no other options.
JUNE 18, 2025
A Targeted Treatment for Carbapenem-Resistant Acinetobacter baumannii
The approval of sulbactam-durlobactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections under the FDA fast-track process sets an important precedent for the development of critical antimicrobials for our most resistant organisms. In this monograph, 2 infectious disease specialists review the clinical trial data and early case reports of this important agent, as well as the updated guidance from the Infectious Diseases Society of America.
APRIL 1, 2025
Antimicrobial Efficacy
This pocket folder is intended to be a reference to describe the potential in vivo activity of various antimicrobial agents when the identity of the infecting organism is known.
MARCH 24, 2025
The Importance of Biofilm Penetration: A Review of Telavancin
Biofilm formation in prosthetic joint infections (PJIs) enhances bacterial resistance to conventional therapies. This article evaluates the unique properties and clinical utility of telavancin for the treatment of PJIs, by addressing infection rates, biofilm penetration, dosing strategies, and safety considerations.
MARCH 4, 2025
The Role of Local Laboratories in HIV and HCV Diagnosis and Prevention
Learn how local laboratories are providing testing services for HIV and HCV and about the significant progress and expanded testing capabilities that are making a difference in patient care.
OCTOBER 4, 2024
Use of Dalbavancin in Optimizing the Management of ABSSSIs in Patients With Obesity or Diabetes
This Special Report reviews data on the use of dalbavancin for the treatment of ABSSSIs to support safety and efficacy in high-risk populations, including obese and diabetic patients.
JULY 9, 2024
Evolution in Guidelines For Protection Against Monkeypox Virus Infection
This Special Report describes the characteristics and transmission of monkeypox virus (MPXV) and outlines the latest immunization practice recommendations, including the use of JYNNEOS, for individuals at risk for MPXV.
MAY 22, 2024
Reducing the Economic Burden of Hospital Admissions in Treating Patients With ABSSSIs
This Special Report reviews the clinical and economic challenges of acute bacterial skin and skin structure infections and describes the efficacy of using dalbavancin in avoiding hospitalization, facilitating quick and early discharge from the emergency department, and reducing costs.
FEBRUARY 1, 2024
The BIOFIRE® Blood Culture Identification 2 Panel: Rapid Diagnostics for Improved Antimicrobial Stewardship and Patient Outcomes
Bloodstream infections alongside sepsis are a leading cause of death globally. Sepsis alone accounts for nearly 1 in 5 of all deaths annually, underscoring the importance of improving time to pathogen identification and optimal antimicrobial treatment. This article will discuss how the fast and accurate results of the BIOFIRE® Blood Culture Identification 2 Panel may contribute to data-driven decision making, improved patient outcomes, and elevated antimicrobial stewardship.
OCTOBER 2, 2023
Microbiota-Based Therapy for the Prevention of Recurrent Clostridioides difficile Infection:
A Primer on REBYOTA®
(fecal microbiota, live-jslm)
This Special Report outlines the challenges of treating Clostridioides difficile infection (CDI) and preventing recurrent CDI, and introduces REBYOTA (fecal-microbiota, live jslm), the first and only single-dose, FDA-approved, microbiota-based live biotherapeutic indicated for prevention of rCDI, as a potential option in restoring the gut microbiome.
AUGUST 29, 2023
